Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission

Open access
Kuhen, Kelli L., Chatterjee, Arnab K., Rottmann, Matthias, Gagaring, Kerstin, Borboa, Rachel, Buenviaje, Jennifer, Chen, Zhong, Francek, Carolyn, Wu, Tao, Nagle, Advait, Barnes, S. Whitney, Plouffe, David, Lee, Marcus C. S., Fidock, David A., Graumans, Wouter, van de Vegte-Bolmer, Marga, van Gemert, Geert J., Wirjanata, Grennady, Sebayang, Boni, Marfurt, Jutta, Russell, Bruce, Suwanarusk, Rossarin, Price, Ric N., Nosten, Francois, Tungtaeng, Anchalee, Gettayacamin, Montip, Sattabongkot, Jetsumon, Taylor, Jennifer, Walker, John R., Tully, David, Patra, Kailash P., Flannery, Erika L., Vinetz, Joseph M., Renia, Laurent, Sauerwein, Robert W., Winzeler, Elizabeth A., Glynne, Richard J., Diagana, Thierry T.·2014·Antimicrobial Agents and Chemotherapy

Abstract

Renewed global efforts toward malaria eradication have highlighted the need for novel antimalarial agents with activity against multiple stages of the parasite life cycle. We have previously reported the discovery of a novel class of antimalarial compounds in the imidazolopiperazine series that have activity in the prevention and treatment of blood stage infection in a mouse model of malaria. Consistent with the previously reported activity profile of this series, the clinical candidate KAF156 shows blood schizonticidal activity with 50% inhibitory concentrations of 6 to 17.4 nM against P. falciparum drug-sensitive and drug-resistant strains, as well as potent therapeutic activity in a mouse models of malaria with 50, 90, and 99% effective doses of 0.6, 0.9, and 1.4 mg/kg, respectively. When administered prophylactically in a sporozoite challenge mouse model, KAF156 is completely protective as a single oral dose of 10 mg/kg. Finally, KAF156 displays potent Plasmodium transmission blocking activities both in vitro and in vivo . Collectively, our data suggest that KAF156, currently under evaluation in clinical trials, has the potential to treat, prevent, and block the transmission of malaria.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.02727-13

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 158

Metadata

Authors
Kuhen, K. L., Chatterjee, A. K., Rottmann, M., Gagaring, K., Borboa, R., Buenviaje, J., Chen, Z., Francek, C., Wu, T., Nagle, A., Barnes, S. W., Plouffe, D., Lee, M. C. S., Fidock, D. A., Graumans, W., van de Vegte-Bolmer, M., van Gemert, G. J., Wirjanata, G., Sebayang, B., Marfurt, J., Russell, B., Suwanarusk, R., Price, R. N., Nosten, F., Tungtaeng, A., Gettayacamin, M., Sattabongkot, J., Taylor, J., Walker, J. R., Tully, D., Patra, K. P., Flannery, E. L., Vinetz, J. M., Renia, L., Sauerwein, R. W., Winzeler, E. A., Glynne, R. J., & Diagana, T. T.
Venue
Antimicrobial Agents and Chemotherapy
Published
2014-09
Volume
58
Issue
9
Pages
5060-5067
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2135797423
Cited by
158
References
3
FWCI
12.87
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission. https://app.cochat.ai/papers/10.1128/aac.02727-13
The paper
Kuhen, K. L., Chatterjee, A. K., Rottmann, M., Gagaring, K., Borboa, R., Buenviaje, J., Chen, Z., Francek, C., Wu, T., Nagle, A., Barnes, S. W., Plouffe, D., Lee, M. C. S., Fidock, D. A., Graumans, W., van de Vegte-Bolmer, M., van Gemert, G. J., Wirjanata, G., Sebayang, B., . . . Diagana, T. T. (2014). KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.02727-13

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.